Humana (NYSE:HUM) Issues FY 2025 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 16.250-16.250 for the period, compared to the consensus earnings per share estimate of 16.910. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday. Piper Sandler boosted their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. TD Cowen raised their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Morgan Stanley decreased their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of “Hold” and an average target price of $292.26.

Humana Stock Performance

Shares of Humana stock opened at $259.93 on Thursday. The company has a 50 day moving average of $273.00 and a 200-day moving average of $295.72. The company has a market cap of $31.30 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities research analysts forecast that Humana will post 16.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.